C4 Therapeutics (CCCC) Stock Price, News & Analysis

Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $3.87 to $4.01
• 50-Day Range: $3.50 to $5.88
• 52-Week Range: $3.38 to $11.88
• Volume: 2.68 million shs
• Average Volume: 1.63 million shs
• Market Capitalization: $278.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.67
• Consensus Rating: Moderate Buy

C4 Therapeutics Stock Analysis - MarketRank™

C4 Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 716th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

C4 Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of C4 Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of C4 Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

C4 Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.18% of the outstanding shares of C4 Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

C4 Therapeutics has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in C4 Therapeutics has recently decreased by 3.04%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

C4 Therapeutics does not currently pay a dividend.

Dividend Growth

C4 Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.18% of the outstanding shares of C4 Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

C4 Therapeutics has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in C4 Therapeutics has recently decreased by 3.04%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.03

News Sentiment

C4 Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.55% of the stock of C4 Therapeutics is held by insiders.

Percentage Held by Institutions

78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CCCC Stock Analysis - Frequently Asked Questions

How have CCCC shares performed this year?

C4 Therapeutics' stock was trading at $3.60 on January 1st, 2025. Since then, CCCC shares have increased by 9.4% and is now trading at $3.94.
View the best growth stocks for 2025 here.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) announced its quarterly earnings data on Thursday, October, 31st. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05. The company earned $15.36 million during the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative net margin of 313.35% and a negative trailing twelve-month return on equity of 42.45%.

When did C4 Therapeutics IPO?

C4 Therapeutics (CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' top institutional investors include Hennion & Walsh Asset Management Inc. (0.32%).
View institutional ownership trends.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of C4 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 2/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CCCC
• CUSIP: N/A
• CIK: 1662579
• Web: www.c4therapeutics.com
• Phone: 617-231-0700
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.67
• High Stock Price Target: $20.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +170.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-132,490,000.00
• Net Margins: -313.35%
• Pretax Margin: -312.52%
• Return on Equity: -42.45%
• Return on Assets: -27.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.31
• Quick Ratio: 6.31

Sales & Book Value

• Annual Sales: $20.76 million
• Price / Sales: 13.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.07 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 70,590,000
• Free Float: 64,554,000
• Market Cap: $278.12 million
• Optionable: Optionable
• Beta: 2.96